Tradition Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tradition Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	463 +14	+3%	+$6.21K	0.01%	472
2026 Q1	$200K	Buy	+449	New	+$209K	0.01%	480
2025 Q2	–	Sell	-426	Closed	-$207K	–	475
2025 Q1	$207K	Buy	+426	New	+$199K	0.02%	404
2024 Q1	–	Sell	-410	Closed	-$167K	–	1173
2023 Q4	$167K	Buy	410 +10	+3%	+$3.69K	0.02%	350
2023 Q3	$139K	Buy	400 +1	+0.3%	+$350	0.02%	366
2023 Q2	$140K	Buy	399 +1	+0.3%	+$337	0.02%	378
2023 Q1	$125K	Buy	398 +9	+2%	+$2.7K	0.02%	381
2022 Q4	$112K	Buy	389 +2	+0.5%	+$610	0.02%	351
2022 Q3	$112K	Buy	387 +359	+1,282%	+$103K	0.02%	343
2022 Q2	$8K	Hold	28	–	–	﹤0.01%	883
2022 Q1	$7K	Hold	28	–	–	﹤0.01%	988
2021 Q4	$6K	Hold	28	–	–	﹤0.01%	1030
2021 Q3	$5K	Sell	28 -100	-78%	-$19.5K	﹤0.01%	1045
2021 Q2	$26K	Hold	128	–	–	﹤0.01%	694
2021 Q1	$28K	Hold	128	–	–	﹤0.01%	564
2020 Q4	$30K	Buy	+128	New	+$29.4K	0.01%	511

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tradition Wealth Management's VRTX Position: Q2 2026 in Review

Tradition Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q2 2026, buying an estimated $6.21K and bringing the position to 463 shares worth $230K. The position accounts for 0.01% of the portfolio, ranked #472.

Tradition Wealth Management first reported a position in VRTX in Q4 2020 and has held it in 16 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Tradition Wealth Management held 463 shares of Vertex Pharmaceuticals worth $230K as of Q2 2026.
Tradition Wealth Management bought 14 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.21K.
Vertex Pharmaceuticals made up 0.01% of Tradition Wealth Management's portfolio in Q2 2026, its #472 holding.
Tradition Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tradition Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.